Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Lemborexant with CYP Modulators and Substrates
NCT02085967Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lemborexant in Insomnia (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 42, Area Under the Concentration-Time Curve from Time Zero to Infinity at Day 42 and 1 more. Started Feb 2014; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02085967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085967.